Abstract
Replacement therapy with plasma derived or recombinant F Ⅷ (rFⅧ) concentrates is only effective way to treat hemophilia A.Currently,the first,second and third generation rFⅧ are commercially available.Of the three products,the third generation rFⅧ products are best,because of no additional human or animal plasma proteins at any period.The use of rFⅧ concentrates has greatly improved the safety of replacement therapy in hemophilia A and reduced the risk of blood-borne pathogen transmission.In this article we review the current knowledge about the three rF Ⅷ concentrates,analyzing their main characteristic and their clinical hemostatic efficacy and safety. Key words: Recombinant factor Ⅲ; Hemophilia; Inhibitor
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
